TCGX Acquisition Corp. Prices $75 Million IPO on Nasdaq

TCGX Acquisition Corp., a special purpose acquisition company (SPAC), announced it has priced its initial public offering of 7.5 million Class A ordinary shares at $10.00 per share. The offering is expected to raise gross proceeds of $75 million, according to a company press release.

The shares are scheduled to begin trading on the Nasdaq Capital Market on August 5, 2026, under the ticker symbol TCGX. The offering is anticipated to close on August 6, 2026, subject to customary closing conditions.

Offering Details

Jefferies is acting as the sole book-running manager for the offering. The company has also granted the underwriter a 45-day option to purchase up to an additional 1,125,000 Class A ordinary shares at the IPO price to cover any over-allotments.

Key terms of the IPO include:

• Shares Offered: 7,500,000 Class A ordinary shares
• Price per Share: $10.00
• Total Proceeds: $75 million (before potential over-allotments)
• Exchange: Nasdaq Capital Market
• Ticker: TCGX

Ad

Notably, investors in this offering will not receive warrants, a common feature in many SPAC IPOs that gives holders the right to purchase more shares at a fixed price in the future.

Company Strategy

TCGX Acquisition Corp. is a blank-check company sponsored by TCGX Sponsor, LLC, an affiliate of TCG Crossover Management, LLC. The company's primary focus for an acquisition target will be in the healthcare and healthcare-related industries, with a particular emphasis on the life sciences and medical technology sectors.

While this is its stated focus, the company's mandate allows it to pursue a business combination in any industry or geographic location. The U.S. Securities and Exchange Commission (SEC) declared the related registration statement effective on August 4, 2026.